Founded in 2019, Altay Therapeutics develops small molecule drugs for a wide range of diseases, with a focus on chronic liver diseases like liver fibrosis and liver cancer.

The company’s small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA, and according to the company have shown exceptional results in several animal models for fibrotic diseases and several cancers.

The company’s initial focus is on finding treatments for chronic inflammatory liver diseases such as NASH and liver cancer and it expects to nominate a lead drug for liver diseases by Q1 of 2021. In addition, pre-clinical studies for prostate cancer and Ewings Sarcoma are said to show great efficacy and the company expects to nominate a lead for its prostate cancer program by Q2 of 2021.

Approach: Platform to identify Novel small molecules inhibitors of transcription factors.

Potential Indications: Chronic inflammatory diseases, Chronic liver diseases, Fibrosis, NASH, Liver cancer, Rheumatoid arthritis, Ulcerative colitis, Prostate cancer, Ewings sarcoma.

Stage: Pre-clinical

The company’s a team that has more than 70 years of small molecule drug development experience, and includes co-founder Dr. Osman Ozes, who led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis.

Subscribe for alerts on new companies featured on Startups.Bio

• U-Ploid BiotechnologiesSeptember 17, 2024
  U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women… Read more: U-Ploid Biotechnologies
• BioTryp TherapeuticsMarch 22, 2024
  BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on… Read more: BioTryp Therapeutics
• Bastion TherapeuticsJanuary 9, 2024
  Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class… Read more: Bastion Therapeutics
• HOVANANovember 22, 2023
  HOVANA is a digital biology company tackling translational dysfunction as a driver… Read more: HOVANA
• CourageneOctober 16, 2023
  Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo… Read more: Couragene
• Function OncologySeptember 21, 2023
  Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional… Read more: Function Oncology